Erdafitinib is a tyrosine kinase inhibitor of fibroblast growth factor receptor 1 through 4 and was approved by the US Food and Drug Administration earlier this year as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2genetic alterations.
A new study looked at the physical activity among patients with metastatic colorectal cancer to see if it affected disease progression and overall survival.
FoundationOne®Liquid can deliver reliable answers faster than tissue testing by analyzing 70 genes and reporting on microsatellite instability high (MSI-H) status from a simple blood draw.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
